Abstract:Lymphomas represent a diverse group of malignancies that emerge from lymphocytes. Despite improvements in diagnosis and treatment of lymphomas of B-cell origin, relapsed and refractory disease represents an unmet clinical need. Therefore, it is of utmost importance to better understand the lymphomas' intrinsic features as well as the interactions with their cellular microenvironment for developing novel therapeutic strategies. In fact, the role of immune-based approaches is steadily increasing and involves amongst others the use of monoclonal antibodies against tumor antigens, inhibitors of immunological checkpoints, and even genetically modified T-cells. Metabolic reprogramming and immune escape both represent well established cancer hallmarks. Tumor metabolism as introduced by Otto Warburg in the early 20th century promotes survival, proliferation, and therapeutic resistance. Simultaneously, malignant cells employ a plethora of mechanisms to evade immune surveillance. Increasing evidence suggests that metabolic reprogramming does not only confer cell intrinsic growth and survival advantages to tumor cells but also impacts local as well as systemic anti-tumor immunity. Tumor and immune cells compete over nutrients such as carbohydrates or amino acids that are critical for the immune cell function. Moreover, skewed metabolic pathways in malignant cells can result in abundant production and release of bioactive metabolites such as lactic acid, kynurenine or reactive oxygen species (ROS) that affect immune cell fitness and function. This "metabolic re-modeling" of the tumor microenvironment shifts anti-tumor immune reactivity toward tolerance. Here, we will review molecular events leading to metabolic alterations in B-cell lymphomas and their impact on anti-tumor immunity.

The Metabolism and Immune Environment in Diffuse Large B-Cell Lymphoma

The Metabolism and Immune Environment in Diffuse Large B-Cell Lymphoma

Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma

Effects of Glucose Metabolism, Lipid Metabolism, and Glutamine Metabolism on Tumor Microenvironment and Clinical Implications

Targeting metabolism to enhance immunotherapy within tumor microenvironment

Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma

Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implications

Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment

Emerging Landscapes of Tumor Immunity and Metabolism

Advances in Understanding of Metabolism of B-Cell Lymphoma: Implications for Therapy

Metabolic Reprogramming Induces Immune Cell Dysfunction in the Tumor Microenvironment of Multiple Myeloma

Macrophages and Metabolic Reprograming in the Tumor Microenvironment

Metabolic regulation of the bone marrow microenvironment in leukemia

Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy

Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment

Linking Immunoevasion and Metabolic Reprogramming in B-Cell–Derived Lymphomas

Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy

Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes

Progress of Studies on Microenvironment of Lymphoma——Review

The immunometabolic landscape of the bone marrow microenvironment in acute myeloid leukemia